In 2012, Domain and Ono Pharmaceutical Co., Ltd. (Osaka – Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).

Domain Therapeutics applied DTect-All™, its proprietary GPCR drug discovery platform and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono supported research activities and gained worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration. Under the terms of the agreement, Domain was eligible for undisclosed upfront, success-based milestones on the research, development milestones and royalties.